Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:146281062" >
Outcomes of older p...
Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials
-
Casulo, C (författare)
-
Dixon, JG (författare)
-
Ou, FS (författare)
-
visa fler...
-
Hoster, E (författare)
-
Peterson, BA (författare)
-
Hochster, HS (författare)
-
Brice, P (författare)
-
Ladetto, M (författare)
-
Hiddemann, W (författare)
-
Marcus, R (författare)
-
Kimby, E (författare)
-
Herold, M (författare)
-
Nielsen, T (författare)
-
Morschhauser, F (författare)
-
Rummel, M (författare)
-
Hagenbeek, A (författare)
-
Vitolo, U (författare)
-
Salles, GA (författare)
-
Shi, Q (författare)
-
Flowers, CR (författare)
-
visa färre...
- 2021-03-22
- 2021
- Engelska.
-
Ingår i: Blood advances. - : American Society of Hematology. - 2473-9537 .- 2473-9529. ; 5:6, s. 1737-1745
- Relaterad länk:
-
https://ashpublicati...
-
visa fler...
-
http://kipublication...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Limited data exist to describe the clinical features and outcomes for elderly patients with follicular lymphoma (FL). The Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) group performed a prospectively planned pooled analysis of individual patient data from first-line randomized controlled trials (RCTs) and examined associations between age (≤70 vs >70 years), clinical characteristics, and FL outcomes. We identified 18 multicenter clinical RCTs in the FLASH database that enrolled elderly patients (>70 years). Primary end points were early disease outcomes, CR24 and CR30, and progression-free survival (PFS) at 24 months (PFS24). Secondary end points were PFS and overall survival (OS). We identified 5922 previously untreated FL patients from 18 RCTs. Patients age >70 years (vs ≤70 years) more commonly had elevated lactate dehydrogenase, hemoglobin <12 g/dL, ECOG PS ≥2, and elevated β2-microglobulin. Median follow-up was 5.6 years. Patients >70 years did not differ from patients ≤70 years in rates of CR24, CR30, or PFS24. With a median OS of 14.6 years for all patients, median OS was 7.4 and 15.7 years for patients >70 and ≤70 years of age, respectively (hazard ratio = 2.35; 95% confidence interval = 2.03-2.73; P < .001). Age >70 years was a significant predictor of OS and PFS due to higher rates of death without progression, but not PFS24, CR24, or CR30. FL patients >70 years treated on trials have similar early disease outcomes to younger patients. There is no disease-specific outcome difference between age groups. Age alone should not disqualify patients from standard treatments or RCTs.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Casulo, C
-
Dixon, JG
-
Ou, FS
-
Hoster, E
-
Peterson, BA
-
Hochster, HS
-
visa fler...
-
Brice, P
-
Ladetto, M
-
Hiddemann, W
-
Marcus, R
-
Kimby, E
-
Herold, M
-
Nielsen, T
-
Morschhauser, F
-
Rummel, M
-
Hagenbeek, A
-
Vitolo, U
-
Salles, GA
-
Shi, Q
-
Flowers, CR
-
visa färre...
- Artiklar i publikationen
-
Blood advances
- Av lärosätet
-
Karolinska Institutet